nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.02.2009 | Original Paper

Impact of different anticancer regimens on biomarkers of angiogenesis in patients with advanced hepatocellular cancer

verfasst von: G. Treiber, T. Wex, P. Malfertheiner

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 2/2009

Einloggen, um Zugang zu erhalten

Abstract

Objective

Advanced hepatocellular cancer (HCC) is a highly vascularised tumor with limited treament options. We wanted to evaluate the impact of different treatments on systemic biomarkers linked to angiogenesis.

Methods

Two subsequent prospective, randomised, phase-I/II trials in patients with advanced HCC were performed. A total of 38 patients was randomised to a total of 4 regimens consisting of 3 cycles of 4 weeks each: Trial 1 included group 1 receiving octreotide 30 mg im on day 1, and group 2 octreotide 30 mg on day 1 plus Imatinib 400 mg po daily; Trial 2 included group 3 with oxaliplatin on day 1 (60 mg–90 mg/m²), and group 4 with oxaliplatin on day 1, 8, 15 (20 mg–30 mg/m²) in combination with octreotide 30 mg on day 1 plus imatinib 400 mg po daily. Primary outcome measure was the relative changes in plasma biomarkers over time.

Results

Time-to-progression and overall survival was not different between the the two study trials. Within group 1–4, the mean relative increase from baseline to week 12 of treatment was 17, 18, 37, and 2% for s-E-selectin; –1, 90, 10, and −9% for VEGF-A; 18, 84, 141, and 74% for PDGF-BB, and 111, 142, 30, and 7% for serum AFP, respectively.

Conclusions

The increase of plasma levels for s-E-selectin and PDGF-BB seen in patients receiving chemotherapy alone may reflect activation of angiogenesis. In contrast, low-dose metronomic chemotherapy in combination with anti-angiogenic drugs seems to correlate with the least increase in biomarkers. Imatinib-octreotide temporarily leads to a decrease in PDGF-BB, whereas octreotide alone had no effect on PDGF-BB plasma levels.

Abou-Alfa GK, Schwartz L, Ricci S et al (2006) Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24:4293–4300PubMedCrossRef

Baker DE (2002) Imatinib mesylate. Rev Gastroenterol Disord 2:75–86PubMed

Becker G, Allgaier HP, Olschewski M, Zahringer A, Blum HE (2007) HECTOR Study Group. Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study. Hepatology 45:9–15PubMedCrossRef

Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D (2003) Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111:1287–1295PubMed

Bruix J, Sherman M (2005) Management of Hepatocellular Carcinoma (AASLD Practice Guideline). Hepatology 42:1208–1236PubMedCrossRef

Byrne GJ, Ghellal A, Iddon J, Blann AD, Venizelos V, Kumar S, Howell A, Bundred NJ (2000) Serum soluble vascular cell adhesion molecule–1: role as a surrogate marker of angiogenesis. J Natl Cancer Inst 92:1329–1336PubMedCrossRef

Cebon J, Findlay M, Hargreaves C, Stockler M, Thompson P, Boyer M, Roberts S, Poon A, Scott AM, Kalff V, Garas G, Dowling A, Crawford D, Ring J, Basser R, Strickland A, Macdonald G, Green M, Nowak A, Dickman B, Dhillon H, Gebski V (2006) Australasian Gastro-Intestinal Trials Group (AGITG) Ag0001H Investigators. Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide. Br J Cancer 95:853–861PubMedCrossRef

Czochra P, Kutzner P, Maass T, Thieringer F, Haennchen M, Schirmacher P, Longerich P, Lohse A, Galle P, Kanzler S (2006) Accelerated tumor progression in chemical carcinogenesis model in PDGF-B transgenic mice. Hepatology 44(Supp 1):A122

Dasgupta P (2004) Somatostatin analogues: multiple roles in cellular proliferation, neoplasia, and angiogenesis. Pharmacol Ther 102:61–85PubMedCrossRef

Dimitroulopoulos D, Xinopoulos D, Tsamakidis K et al (2002) The role of sandostatin LAR in treating patients with advanced hepatocellular cancer. Hepatogastroenterology 49:1245–1250PubMed

Dimitroulopoulos D, Xinopoulos D, Tsamakidis K, Zisimopoulos A, Andriotis E, Panagiotakos D, Fotopoulou A, Chrysohoou C, Bazinis A, Daskalopoulou D, Paraskevas E (2007) Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: randomized placebo-controlled trial. World J Gastroenterol 13:3164–3170PubMed

El-Serag HB, Davila JA, Petersen NJ et al (2003) The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 139:817–823PubMed

Florio T, Morini M, Villa V et al (2003) Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor–3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities. Endocrinology 144:1574–1584PubMedCrossRef

Garcia Dela Torre N, Wass JA, Turner HE (2002) Antiangiogenic effects of somatostatin analogues. Clin Endocrinol 57:425–441CrossRef

Homsi J, Daud AI (2007) Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors. Cancer Control 14:285–294PubMed

Jia WD, Xu GL, Sun HC et al (2003a) Effect of octreotide on angiogenesis induced by hepatocellular carcinoma in vivo. Hepatobiliary Pancreat Dis Int 2:404–409PubMed

Jia WD, Xu GL, Xu RN et al (2003b) Octreotide acts as an antitumor angiogenesis compound and suppresses tumor growth in nude mice bearing human hepatocellular carcinoma xenografts. J Cancer Res Clin Oncol 129:327–334PubMedCrossRef

Kerbel S, Kamen BA (2004) The anti-angiogenic basis of metronomic chemotherapy. Nat Rev 4:423–436

Kouroumalis E, Skordilis P, Thermos K et al (1998) Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut 42:442–447PubMedCrossRef

Kwak BK, Shim HJ, Park ES et al (2001) Hepatocellular carcinoma: correlation between vascular endothelial growth factor level and degree of enhancement by multiphase contrast-enhanced computed tomography. Invest Radiol 36:487–492PubMedCrossRef

Lahlou H, Saint-Laurent N, Esteve JP et al (2003) SST2 Somatostatin receptor inhibits cell proliferation through Ras-, Rap1-, and B-Raf-dependent ERK2 activation. J Biol Chem 278:39356–39371PubMedCrossRef

Llovet J, Ricci S, Mazzaferro V, Hilgard P, Raoul J, Zeuzem S, Poulin-Costello M, Moscovici M, Voliotis D, Bruix J. Sorafenib improves survival in advanced Hepatocellular Carcinoma (HCC): Results of a Phase III randomized placebo-controlled trial (SHARP trial). J Clin Oncol 2007, ASCO Annual Meeting Proceedings Part I. vol 25, No. 18S (June 20 Supplement), 2007: LBA1

Llovet JM, Burroughs A, Bruix J (2003) Hepatocellular carcinoma. Lancet 362:1907–1917PubMedCrossRef

Mann CD, Neal CP, Garcea G, Manson MM, Dennison AR, Berry DP (2007) Prognostic molecular markers in hepatocellular carcinoma: a systematic review. Eur J Cancer 43:979–992PubMedCrossRef

Pan DY, Qiao JG, Chen JW et al (2003) Tamoxifen combined with octreotide or regular chemotherapeutic agents in treatment of primary liver cancer: a randomized controlled trial. Hepatobiliary Pancreat Dis Int 2:211–215PubMed

Pietras K (2004) Increasing tumor uptake of anticancer drugs with imatinib. Semin Oncol 31(2 Suppl 6):18–23PubMedCrossRef

Pietras K, Hanahan D (2005) A Multitargeted, Metronomic, and Maximum-Tolerated Dose ‘‘Chemo-Switch’’ Regimen is Antiangiogenic, Producing Objective Responses and Survival Benefit in a Mouse Model of Cancer. J Clin Oncol 23:939–952PubMedCrossRef

Pietras K, Rubin K, Sjoblom T, Buchdunger E, Sjoquist M, Heldin CH, Ostman A (2002) Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 62:5476–5484PubMed

Pietras K, Sjoblom T, Rubin K, Heldin CH, Ostman A (2003) PDGF receptors as cancer drug targets. Cancer Cell 3:439–443PubMedCrossRef

Plentz RR, Tillmann HL, Kubicka S, Bleck JS, Gebel M, Manns MP, Rudolph KL (2005) Hepatocellular carcinoma and octreotide: treatment results in prospectively assigned patients with advanced tumor and cirrhosis stage. J Gastroenterol Hepatol 20:1422–1428PubMedCrossRef

Poon RT, Ng IO, Lau C et al (2001) Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study. Ann Surg 233:227–235PubMedCrossRef

Poon RT, Lau C, Yu WC et al (2004) High serum levels of vascular endothelial growth factor predict poor response to transarterial chemoembolization in hepatocellular carcinoma: a prospective study. Oncol Rep 11:1077–1084PubMed

Rabe C, Pilz T, Allgaier HP et al (2002) Clinical outcome of a cohort of 63 patients with hepatocellular carcinoma treated with octreotide. Z Gastroenterol 40:395–400PubMedCrossRef

Raderer M, Hejna MH, Muller C et al (2000) Treatment of hepatocellular cancer with the long acting somatostatin analog lanreotide in vitro and in vivo. Int J Oncol 16:1197–1120PubMed

Faivre SJ, Raymond E, Douillard J, Boucher E, Lim HY, Kim JS, Lanzalone S, Lechuga MJ, Sherman L, Cheng A. Assessment of safety and drug-induced tumor necrosis with sunitinib in patients (pts) with unresectable hepatocellular carcinoma (HCC). J Clin Oncol 2007, ASCO Annual Meeting Proceedings Part I. vol 25, No. 18S (June 20 Supplement), 2007: 3546

Samonakis DN, Moschandreas J, Arnaoutis T et al (2002) Treatment of hepatocellular carcinoma with long acting somatostatin analogues. Oncol Rep 9:903–907PubMed

Slijkhuis W, Stadheim L, Hassoun Z et al (2005) Octreotide therapy for advanced hepatocellular carcinoma. J Clin Gastroenterol 39:333–338PubMedCrossRef

Treiber G (2001) Systemic treatment of hepatocellular carcinoma. Dig Dis 19:311–323PubMedCrossRef

Treiber G, Wex T, Rocken C, Fostitsch P, Malfertheiner P (2006) Impact of biomarkers on disease survival and progression in patients treated with octreotide for advanced hepatocellular carcinoma. J Cancer Res Clin Oncol 132:699–708PubMedCrossRef

Treiber G, Rocken C, Wex T, Malfertheiner P (2007) Octreotide alone or in combination with rofecoxib as palliative treatment for advanced hepatocellular cancer. Z Gastroenterol 45:369–377PubMedCrossRef

Treiber G, Wex T, Schleyer E, Troeger U, Hosius C, Malfertheiner P (2008) Imatinib for Hepatocellular Cancer—Focus on Pharmacokinetic/Pharmacodynamic Modelling and Liver Function. Cancer Lett 260:146–154PubMedCrossRef

Verset G, Verslype C, Reynaert H, Borbath I, Langlet P, Vandebroek A, Peeters M, Houbiers G, Francque S, Arvanitakis M, Van Laethem JL (2007) Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study. Br J Cancer 97:582–588PubMedCrossRef

Yuen MF, Poon RT, Lai CL et al (2002) A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology 36:687–691PubMedCrossRef

Zhu AX, Blaszkowsky LS, Ryan DP, Clark JW, Muzikansky A, Horgan K, Sheehan S, Hale KE, Enzinger PC, Bhargava P, Stuart K (2006) Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 24:1898–1903PubMedCrossRef

Titel: Impact of different anticancer regimens on biomarkers of angiogenesis in patients with advanced hepatocellular cancer
verfasst von: G. Treiber
T. Wex
P. Malfertheiner
Publikationsdatum: 01.02.2009
Verlag: Springer-Verlag
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 2/2009
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-008-0443-x

Springer Medizin

Impact of different anticancer regimens on biomarkers of angiogenesis in patients with advanced hepatocellular cancer

Abstract

Objective

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Objective

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2009

Reduced expression of C/EBPα protein in hepatocellular carcinoma is associated with advanced tumor stage and shortened patient survival

Study on the mutations in the D-loop region of mitochondrial DNA in cervical carcinoma

Four consecutive multicenter phase II trials of adjuvant chemoradiation in patients with completely resected high-risk gastric cancer: the experience of the German AIO/ARO/CAO group

Beta-hCG/LH receptor (b-HCG/LH-R) expression is increased in invasive versus preinvasive breast cancer: implications for breast carcinogenesis?

Loss of PTEN function may account for reduced proliferation pathway sensitivity to LY294002 in human prostate and bladder cancer cells

Nerve growth factor/nuclear factor-κB pathway as a therapeutic target in breast cancer

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie